News | May 07, 2012

WBR Halves Dose, Acquisition Time in Gated SPECT Studies

Wide Beam Reconstruction Protocol Addresses Growing Concern About Radiation Exposure

May 7, 2012 — A software program for the reconstruction of nuclear medicine images, Wide Beam Reconstruction (WBR) reduces the required radiopharmaceutical dose and image acquisition time by 50 percent for diagnostic quality myocardial perfusion imaging (MPI) single photon emission computed tomography (SPECT) compared to conventional techniques, according to a new study published in the March/April 2011 issue of the Journal of Nuclear Cardiology.

Researchers found that with either half the dose of Tc-99m sestamibi or half the acquisition time, WBR resulted in image quality superior to processing with today’s widely used ordered subset expectation maximization (OSEM) software. The study was conducted at St. Luke’s-Roosevelt Hospital and Columbia University College of Physicians and Surgeons in New York City.

“The escalating radiation levels of today’s advanced imaging exams is causing growing concern among the medical community and the public at large,” said Gordon DePuey, M.D., lead researcher and director of nuclear medicine at St. Luke’s-Roosevelt Hospital and professor of radiology at Columbia University. “There is significant pressure to minimize radiation dose, particularly for MPI nuclear SPECT exams.” In addition, the ongoing shortages of radiopharmaceuticals due to nuclear reactor downtime compound the need to minimize dosage.

Developed by UltraSPECT, based in Haifa, Israel, WBR is a reconstruction algorithm incorporating depth-dependent resolution recovery and image noise modeling to deliver a higher quality image with lower count density data. In the new MPI study, researchers evaluated images from 156 patients undergoing myocardial perfusion SPECT with a standard full-time acquisition protocol processed with routine OSEM methods. The same 156 patients underwent half-time acquisition, and the data were processed with the WBR algorithm. The images were acquired both at rest and following exercise or pharmacologic stress.

A second study group of 160 patients received half of the standard radiopharmaceutical dose, with images acquired for the full standard acquisition time. These were processed using WBR only. All images were rated for quality by two observers unaware of the acquisition and processing methods. For both the lower dose and abbreviated acquisition time images, grading parameters included myocardial count density and uniformity, endocardial and epicardial edge definition, visualization and definition of the right ventricle, and background noise. For the abbreviated acquisition time images only, SPECT perfusion defects also were examined.

Overall, WBR half-time and half-dose image quality was judged as superior to OSEM image quality in both arms of the study. There was no statistically significant difference between the two SPECT protocols in identifying the extent or severity of perfusion defects.

“The results of this study demonstrate that WBR is a powerful means of reducing dose without sacrificing image quality and diagnostic accuracy. I would recommend that all nuclear medicine laboratories adopt some strategy for reducing patient radiation exposure incorporating WBR or others techniques that have proven effective,” said DePuey.

For more information visit: www.ultraspect.com


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now